Bionpharma Antitrust Claims Still Stand in Epaned Patent Suit

Bionpharma Inc.'s claims that Azurity Pharmaceuticals Inc. patent lawsuits against it are anticompetitive and baseless will be permitted to continue in a “third wave” of litigation over Bionpharma’s proposed copy of the blood pressure drug Epaned.

Judge Mitchell S. Goldberg of the US District Court for the District of Delaware said Bionpharma plausibly alleged its antitrust counterclaims, denying on Wednesday Azurity’s bid to dismiss them.

Bionpharma argued that Azurity sought to “improperly maintain a monopoly” by engaging it in “burdensome and costly litigation.”

Azurity has filed seven lawsuits over the proposed Epaned generic in three separate courts to date, according ...